Beckwith-Wiedemann Syndrome | CHOP Research Institute
 

Beckwith-Wiedemann Syndrome

The Center for Human Phenomic Science Sleep Core supports clinical sleep research with a staff of pediatric sleep technologists, designated research beds, and state-of-the-art equipment or various sleep-related research initiatives.

Published on
Dec 10, 2021
Our research news highlights a study about sequencing bone marrow DNA after CAR T-cell therapy and how it accurately predicts leukemia relapse.

Children and adults with Beckwith-Wiedemann syndrome may be at increased risk for sleep apnea than other children.

The Kalish Lab studies the genetic and epigenetic causes of growth disorders and cancer predisposition. The lab focuses on studying Beckwith-Wiedemann syndrome (BWS), the most common epigenetic and cancer predisposition disorder, and also runs the BWS registry and biorepository.

Actively engaging in research dedicated to better understanding of how to treat sleep problems in children.

Facilitating interaction between Beckwith-Wiedemann Syndrome (BWS) clinical experts, scientists, patient advocates, and BWS families to improve diagnosis, quality of care, and knowledge about BWS.

Dr. Cielo conducted clinical and translational research related to the mechanisms and effects of obstructive sleep apnea in children, with a specific focus on infant populations, children with craniofacial conditions, and the use of MRI and other imaging modalities to understand structural contributors to obstructive sleep apnea in children.

E-mail:
cieloc [at] chop.edu

Dr. Kalish's research focuses on understanding the molecular and epigenetic mechanisms that contribute to the predisposition to cancer that is characteristic of pediatric patients with rare imprinted gene disorders, including the overgrowth disorder Beckwith-Wiedemann syndrome (BWS).

E-mail:
kalishj [at] chop.edu

Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.

E-mail:
stanleyc [at] chop.edu
Published on
Oct 18, 2018
New St. Baldrick's research grant awards support our investigators' exploration of new approaches to pediatric cancer.